Management and board of directors

---

Christopher J. Morl is President and CEO of Bactria Pharmaceuticals, LLC.  Mr. Morl has more than 25-years of experience in strategic and operational roles in private biotechnology and multinational pharmaceutical companies.  Prior to joining Bactria, Mr. Morl was Chief Business Officer at Deciphera Pharmaceuticals, Inc., a publicly traded company focused on the discovery, development, and commercialization of kinase inhibitors for the treatment of cancers.  Prior to joining Deciphera, Mr. Morl was a member of the senior executive team at miRagen Therapeutics, Inc., an oligonucleotide therapeutics discovery and development company, serving as the Chief Operating Officer from May 2016 to October 2016 and Chief Business Officer from May 2013 to May 2016.  Prior to joining miRagen, Mr. Morl served in senior management roles at various biotechnology companies, including as Chief Operating Officer at Ambit Biosciences Corporation, an oncology-focused biotechnology company engaged in discovering and developing targeted small molecule kinase inhibitors, and as Vice President of Business Development at Agensys, Inc., prior to and following the acquisition of Agensys Inc. by Astellas Pharma, Inc.  Before joining Agensys, he served for 20 years in positions of increasing responsibility in research, sales, marketing, business development and county management at GSK plc that included commercialization of antibiotics.  From February 2010 to December 2016, Mr. Morl served as an Independent Director of Alethia Biotherapeutics.  Mr. Morl earned a B.Sc. (Hons) in Applied Biology and Pharmacology from the University of London (UK) and an M.B.A. from Cranfield School of Management (UK). 

Dr. Corrie Detweiler is a Professor of Molecular Cellular and Developmental Biology at University of Colorado Boulder, a leading expert in bacterial pathogenesis and the discovery of chemicals with anti-Gram-negative bacterial activity, and a co-founder of Bactria Pharmaceuticals, LLC.  The goal of the Detweiler Lab is to discover new chemicals entities that possess the requisite anti-microbial properties to be developed into novel therapeutic treatments.  Under Dr. Detweiler’s leadership the Lab established that Salmonella enterica serovar Typhimurium resides within hemophagocytes, macrophages that have engulfed red and white blood cells, and demonstrated that these cells express markers consistent with an anti-inflammatory phenotype.  This expertise with macrophages was used to develop a new platform, SAFIRE, (Screen for Anti-infectives using Fluorescence microscopy of IntracellulaR Enterobacteriaceae) to screen for hit compounds that have potential as antimicrobials and as chemical probes of host-pathogen interactions. The Lab is currently establishing compound mechanism of action with a focus on bacterial efflux pump inhibitors and small molecules that damage bacterial inner membranes.  Dr. Detweiler participates in NIH study sections 2-4 times per year and is the Editor in Chief of the American Society for Microbiology’s Microbiology and Molecular Biology Reviews (MMBR) journal. She also co-designed and taught an on-going CURE (course undergraduate research experience) based on antibiotic discovery.